Insilico Medicine (ISPC)

Insilico Medicine (ISPC)

Preis: 2.75

Unternehmen und Geschäftsmodell

Insilico Medicine is a biotechnology company focused on drug discovery and development using artificial intelligence. Its core products include AI-driven platforms for target identification, drug design, and preclinical development. The company operates primarily in the healthcare sector, with major revenue sources stemming from partnerships, collaborations, and research grants aimed at advancing therapeutic solutions for various diseases.

Anlageprofil

The investment profile of Insilico Medicine is more aligned with growth investors due to its focus on innovative technologies and potential for future revenue generation. However, the high volatility and significant risks associated with its operations may not appeal to conservative investors. The stock may be suitable for those with a medium to long-term investment horizon, seeking exposure to the biotech sector.

Offizielle Website

Fundamentale Kennzahlen (experimentell)

EPS (TTM) — Gewinn pro Aktie der letzten 12 Monate, $
-326.00 Risiko
Umsatz QoQ — Umsatzwachstum im Quartalsvergleich
201.4%
EPS-Überraschung
84.5% besser als erwartet
20d Volatilität
4.7% stabil
FMP / FinFeed-Daten aktualisiert: 2026-06-09
Empf.: Verkaufen Potenzial: 30 Risiko: 85 Aktualisiert: 2026-06-11 05:21
Wie die Empfehlung funktioniert
Warum KI so denkt:
High volatility and negative momentum raise significant concerns.

Im Portfolio verfolgen

Preischart

KI-Empfehlung Analystenprognose Kalenderereignis Positives Signal Negatives Signal Neutral / Update Halten / informativ B My buy S My sell
Änderungen der AI-Empfehlung
Datum Vorher Nachher Grund
2026-06-03 02:44 Halten Verkaufen High volatility and negative momentum raise significant concerns.
2026-05-16 02:53 Verkaufen Halten High volatility and negative fundamentals raise concerns.
2026-05-08 15:31 Verkaufen scenario_deterioration
Insilico Medicine (ISPC) Eli Lilly

Фармацевтический гигант Eli Lilly (LLY) заключил сделку на $2.75 миллиарда с Insilico Medicine для вывода на рынок препаратов, разработанных с помощью ИИ

Американская фармацевтическая компания Eli Lilly заключила сделку на сумму $2.75 миллиарда с гонконгской Insilico Medicine для вывода на глобальный рынок лекарств, разработанных с использованием искусственного интеллекта.